Search

Your search keyword '"Ishiwata, Tsukasa"' showing total 75 results
Start Over Author "Ishiwata, Tsukasa"
75 results on '"Ishiwata, Tsukasa"'

63. Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP)

Author

Ishiwata, Tsukasa, primary, Ebata, Takahiro, additional, Iwasawa, Shunichiro, additional, Matsushima, Jun, additional, Ota, Satoshi, additional, Nakatani, Yukio, additional, Tsushima, Kenji, additional, Tada, Yuji, additional, Tatsumi, Koichiro, additional, and Takiguchi, Yuichi, additional

Published
2017
Full Text
View/download PDF

64. Abstract 239: Alteration of drug sensitivity according to the induction and reversion of epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cell lines harboring an EGFR mutation

Author

Kurimoto, Ryota, primary, Iwasawa, Shunichiro, additional, Ebata, Takahiro, additional, Ishiwata, Tsukasa, additional, Sekine, Ikuo, additional, Tada, Yuji, additional, Tatsumi, Koichiro, additional, Koide, Shuhei, additional, Iwama, Atsushi, additional, and Takiguchi, Yuichi, additional

Published
2016
Full Text
View/download PDF

66. Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation

Author

KURIMOTO, RYOTA, primary, IWASAWA, SHUNICHIRO, additional, EBATA, TAKAHIRO, additional, ISHIWATA, TSUKASA, additional, SEKINE, IKUO, additional, TADA, YUJI, additional, TATSUMI, KOICHIRO, additional, KOIDE, SHUHEI, additional, IWAMA, ATSUSHI, additional, and TAKIGUCHI, YUICHI, additional

Published
2016
Full Text
View/download PDF

68. Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study

Author

Abe,Mitsuhiro, Tsushima,Kenji, Matsumura,Takuma, Ishiwata,Tsukasa, Ichimura,Yasunori, Ikari,Jun, Terada,Jiro, Tada,Yuji, Sakao,Seiichirou, Tanabe,Nobuhiro, Tatsumi,Koichiro, Abe,Mitsuhiro, Tsushima,Kenji, Matsumura,Takuma, Ishiwata,Tsukasa, Ichimura,Yasunori, Ikari,Jun, Terada,Jiro, Tada,Yuji, Sakao,Seiichirou, Tanabe,Nobuhiro, and Tatsumi,Koichiro

Abstract

Mitsuhiro Abe, Kenji Tsushima, Takuma Matsumura, Tsukasa Ishiwata, Yasunori Ichimura, Jun Ikari, Jiro Terada, Yuji Tada, Seiichirou Sakao, Nobuhiro Tanabe, Koichiro Tatsumi Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan Purpose: Acute exacerbation (AE) is an important outcome of idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). Recombinant human soluble thrombomodulin (rhTM) is a new drug for the treatment of disseminated intravascular coagulation in Japan. The objective of this study was to evaluate the efficacy of rhTM for AE of IPF/NSIP.Methods: Twenty-two patients with AE-idiopathic interstitial pneumonia (16 patients with IPF and six patients with NSIP) were enrolled in our study. Among them, eleven patients were treated with rhTM (rhTM group), and eleven patients were treated without rhTM (non-rhTM group). Patients admitted to our hospital prior to December 2013 were treated with rhTM, while those admitted after January 2014 were treated without rhTM. The primary endpoint was mortality at 90 days after AE treatment. The secondary endpoint was the safety of rhTM for AE-IPF/AE-NSIP. In addition, we examined prognostic factors of AE-IPF/AE-NSIP.Results: The mortality rate was significantly lower in the rhTM group than in the non-rhTM group (mortality rate at 90 days: 36% vs 90%, P=0.023; median survival time: not reached vs 15.0 days, P=0.019). A univariate analysis revealed the respiratory rate (hazard ratio [HR] 1.09, 95% confidence interval [CI] 1.00–1.18, P=0.039) and rhTM administration (HR 0.21, 95% CI 0.06–0.77, P=0.013) as predictors of mortality at 90 days, and a multivariate analysis identified rhTM administration (HR 0.025, 95% CI 0.0006–0.94, P=0.046) as an independent predictor of mortality at 90 days. No serious adverse events were observed.Conclusion: The administration of rhTM is associated with reduct

Published
2015

69. Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study

Author

Tsushima, Kenji, primary, Abe, Mitsuhiro, additional, Matsumura, Takuma, additional, Ishiwata, Tsukasa, additional, Ichimura, Yasunori, additional, Ikari, Jun, additional, Terada, Jiro, additional, Tada, Yuji, additional, Sakao, Seiichirou, additional, Tanabe, Nobuhiro, additional, and Tatsumi, Koichiro, additional

Published
2015
Full Text
View/download PDF

70. Pulmonary Arterial Hypertension as the First Manifestation in a Patient with Hereditary Hemorrhagic Telangiectasia

Author

Ishiwata, Tsukasa, primary, Terada, Jiro, additional, Tanabe, Nobuhiro, additional, Abe, Mitsuhiro, additional, Sugiura, Toshihiko, additional, Tsushima, Kenji, additional, Tada, Yuji, additional, Sakao, Seiichiro, additional, Kasahara, Yasunori, additional, Nakanishi, Norifumi, additional, Morisaki, Hiroko, additional, and Tatsumi, Koichiro, additional

Published
2014
Full Text
View/download PDF

74. Feasibility of computed tomography-derived surgical margin assessment in an ex vivo sublobar lung resection model.

Author

Kitazawa S, Bernards N, Gregor A, Sata Y, Hiraishi Y, Ogawa H, Koga T, Ishiwata T, Aragaki M, Yokote F, Effat A, Kazlovich K, Weersink R, Cabanero M, Sato Y, and Yasufuku K

Abstract

Objectives: Computed tomography (CT) imaging of a sublobar resection specimen may inform intraoperative surgical margin assessment. However, consistency with final pathological margins has not been previously evaluated. In this study, we investigated the concordance between surgical margin measurements by CT versus pathology measurements using an ex vivo sublobar lung resection model., Methods: Pig lung wedge samples containing agarose pseudotumours were harvested. CT images were acquired following specimen inflation. The specimen was bisected along the same plane observed by CT for accurate comparison with pathological surgical margin measurement. The bisected samples were then fixed in formalin before preparing haematoxylin & eosin slides. Surgical margin length at four distinct stages (CT, gross pre-formalin fixation, gross post-formalin fixation and pathology) were measured and compared., Results: A total of 50 lung specimens were analysed. After specimen processing, Surgical margin length decreased in 94% (47/50) and increased in 6% (3/50) of samples. Mean surgical margin lengths were as follows: CT 14.0 mm (range: 4.5-28.3 mm), gross pre-formalin fixation 13.0 mm (range: 4.0-25.0 mm), gross post-formalin fixation 12.1 mm (range: 2.5-26.0 mm) and pathology 10.9 mm (range: 1.0-23.4 mm). There was an average -23.8% (range: +11 to -82%) change in surgical margin length from CT to final pathology (P < 0.001)., Conclusions: While CT-based surgical margin measurement is feasible, we observed an average 23.8% discordance when compared to final pathology measurement. Surgeons must be aware that the CT-derived surgical margin generally overestimates the pathology-derived surgical margin., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.)

Published
2024
Full Text
View/download PDF

75. Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study.

Author

Abe M, Tsushima K, Matsumura T, Ishiwata T, Ichimura Y, Ikari J, Terada J, Tada Y, Sakao S, Tanabe N, and Tatsumi K

Subjects
Aged, Aged, 80 and over, Disease Progression, Female, Humans, Idiopathic Pulmonary Fibrosis diagnosis, Idiopathic Pulmonary Fibrosis mortality, Kaplan-Meier Estimate, Lung Diseases, Interstitial diagnosis, Lung Diseases, Interstitial mortality, Male, Middle Aged, Multivariate Analysis, Proportional Hazards Models, Prospective Studies, Recombinant Proteins therapeutic use, Respiratory System Agents adverse effects, Risk Factors, Time Factors, Treatment Outcome, Idiopathic Pulmonary Fibrosis drug therapy, Lung Diseases, Interstitial drug therapy, Respiratory System Agents therapeutic use, Thrombomodulin therapeutic use
Abstract

Purpose: Acute exacerbation (AE) is an important outcome of idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). Recombinant human soluble thrombomodulin (rhTM) is a new drug for the treatment of disseminated intravascular coagulation in Japan. The objective of this study was to evaluate the efficacy of rhTM for AE of IPF/NSIP., Methods: Twenty-two patients with AE-idiopathic interstitial pneumonia (16 patients with IPF and six patients with NSIP) were enrolled in our study. Among them, eleven patients were treated with rhTM (rhTM group), and eleven patients were treated without rhTM (non-rhTM group). Patients admitted to our hospital prior to December 2013 were treated with rhTM, while those admitted after January 2014 were treated without rhTM. The primary endpoint was mortality at 90 days after AE treatment. The secondary endpoint was the safety of rhTM for AE-IPF/AE-NSIP. In addition, we examined prognostic factors of AE-IPF/AE-NSIP., Results: The mortality rate was significantly lower in the rhTM group than in the non-rhTM group (mortality rate at 90 days: 36% vs 90%, P=0.023; median survival time: not reached vs 15.0 days, P=0.019). A univariate analysis revealed the respiratory rate (hazard ratio [HR] 1.09, 95% confidence interval [CI] 1.00-1.18, P=0.039) and rhTM administration (HR 0.21, 95% CI 0.06-0.77, P=0.013) as predictors of mortality at 90 days, and a multivariate analysis identified rhTM administration (HR 0.025, 95% CI 0.0006-0.94, P=0.046) as an independent predictor of mortality at 90 days. No serious adverse events were observed., Conclusion: The administration of rhTM is associated with reductions in mortality in patients with AE-IPF/NSIP, without causing adverse events.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results